Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 2.95 AUD 8.06% Market Closed
Market Cap: 3.8B AUD

Mesoblast Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mesoblast Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Mesoblast Ltd
ASX:MSB
Cash from Operating Activities
-$50m
CAGR 3-Years
9%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Cash from Operating Activities
-AU$45.5m
CAGR 3-Years
-15%
CAGR 5-Years
-33%
CAGR 10-Years
-19%
Opthea Ltd
ASX:OPT
Cash from Operating Activities
-$158.6m
CAGR 3-Years
-31%
CAGR 5-Years
-95%
CAGR 10-Years
-41%
CSL Ltd
ASX:CSL
Cash from Operating Activities
$3.6B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
10%
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Operating Activities
AU$27.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash from Operating Activities
-AU$51.6m
CAGR 3-Years
-33%
CAGR 5-Years
-55%
CAGR 10-Years
-35%
No Stocks Found

Mesoblast Ltd
Glance View

Market Cap
3.8B AUD
Industry
Biotechnology

Mesoblast Ltd., a biotechnology company based in Australia, is navigating the frontier of regenerative medicine with its innovative approach to cell therapy. Founded in 2004, Mesoblast has carved a niche for itself by concentrating on the development and commercialization of allogeneic cellular medicines derived from mesenchymal lineage adult stem cells. These stem cells are pivotal in regenerative therapy due to their remarkable ability to differentiate, reduce inflammation, and promote tissue repair. Mesoblast harnesses this potential to address critical medical conditions, including cardiovascular diseases, spine diseases, immune-mediated diseases, and some rare pediatric conditions. By developing proprietary technology, the company aims to produce off-the-shelf therapies that can be readily available to patients, avoiding the complexities and delays often associated with personalized cellular therapies. The company’s revenue model hinges on the development of its extensive pipeline of products, with an eye towards capturing significant market opportunities across multiple therapeutic areas. Revenues are primarily anticipated from three avenues: collaborations with major pharmaceutical companies, licensing agreements, and, eventually, product sales upon regulatory approval. Mesoblast's strategic partnerships often involve substantial upfront payments, milestone payments, and royalties on the sale of licensed products. For instance, collaborations with giants like Grunenthal in Europe have fortified its research and funding capabilities. Meanwhile, Mesoblast is also committed to expanding its product commercialization capabilities to strategically manage its transition from a research-centered entity to a biopharmaceutical pioneer with marketed therapies. This dual-focused strategy aspires to deliver shareholder value while advancing the horizons of medical treatment.

MSB Intrinsic Value
2.13 AUD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Mesoblast Ltd's Cash from Operating Activities?
Cash from Operating Activities
-50m USD

Based on the financial report for Jun 30, 2025, Mesoblast Ltd's Cash from Operating Activities amounts to -50m USD.

What is Mesoblast Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
0%

Over the last year, the Cash from Operating Activities growth was -3%. The average annual Cash from Operating Activities growth rates for Mesoblast Ltd have been 9% over the past three years .

Back to Top